Novo Nordisk to Unveil New Hemophilia Clinical Data in Paris

The company’s presentation, scheduled for July 11–15, includes extensive analyses from the phase 3 FRONTIER4 study. Researchers will disclose interim results regarding denecimig’s performance in adults, adolescents, and children, specifically focusing on various dosing frequencies ranging from weekly to once-monthly administration. Beyond the FRONTIER4 data, the firm is set to introduce findings from the explorer10 study, which evaluates the safety and efficacy of concizumab in pediatric patients under 11 years of age who live with hemophilia A or B and inhibitors.

Martin Holst Lange, executive vice president for Research & Development, emphasized that the data reflects a long-standing commitment to addressing the specific daily realities of the hemophilia community. While denecimig remains an investigational therapy—currently under review by the U.S. Food and Drug Administration following a September 2025 submission—the upcoming presentations aim to demonstrate how person-centric research can improve bleed control and thrombin generation. The congress will also feature broader real-world evidence, including patient-reported outcomes and studies on the indirect cost burden of the condition in the United States.